Mablink Bioscience receives €31M series A funding for ADC pipeline
French biotech company Mablink Bioscience has raised €31 million ($30.3 million) in series A funding…
Check out the latest antibody-drug conjugate news. This section covers the latest updates on approvals, regulations, deals, and antibody–drug conjugate (ADC) technology.
French biotech company Mablink Bioscience has raised €31 million ($30.3 million) in series A funding…
China-based Hutchmed has started a phase 2/3 trial of sovleplenib in adults with a disorder…
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the…
Pheon Therapeutics launched today (September 28) following the closing of a $68 million series A…
Despite its meteoric growth in the last twenty years, cancer immunotherapy research is hamstrung by…
Dutch biotech Synaffix B.V. and German Emergence Therapeutics announced today (September 6) they have entered…
Hereditary angioedema (HAE), a condition that causes recurrent attacks of severe swelling, could be prevented…
A global collaboration was announced today (August 9) between Mersana Therapeutics Inc and GSK plc…
Formulations of a drug that can help a number of inflammatory diseases including rheumatoid arthritis…
Patients with ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma could benefit from an…
The U.S. company Manifold Bio has raised $40 million in a Series A round to…
A company from South Korea has signed a research collaboration and license agreement with a…